Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD 17.45
+0.58 (3.44%)
Sep 17, 2026, 4:12 PM AEST
Telix Pharmaceuticals Ratios and Metrics
Market cap in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5,929 | 3,794 | 8,238 | 3,263 | 2,300 | 2,209 | |
Market Cap Growth | 25.15% | -53.95% | 152.44% | 41.89% | 4.10% | 108.44% |
Enterprise Value | 6,403 | 4,116 | 8,141 | 3,145 | 2,180 | 2,161 |
Last Close Price | 17.45 | 11.20 | 24.61 | 10.08 | 7.27 | 7.75 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 126.56 | - | 151.34 | 528.32 | - | - |
Forward PE | 405.32 | 282.12 | 87.27 | 32.83 | - | - |
PS Ratio | 4.60 | 3.15 | 9.87 | 6.68 | 14.37 | 290.85 |
PB Ratio | 8.41 | 6.09 | 14.44 | 21.66 | 28.75 | 1023.78 |
P/TBV Ratio | - | - | 53.62 | 80.58 | 109.40 | - |
P/FCF Ratio | - | - | 277.46 | 279.08 | - | - |
P/OCF Ratio | - | - | 185.44 | 155.76 | - | - |
PEG Ratio | - | 0.48 | - | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.97 | 3.42 | 9.75 | 6.43 | 13.62 | 284.54 |
EV/EBITDA Ratio | 57.10 | 84.57 | 84.48 | 56.13 | - | - |
EV/EBIT Ratio | 80.16 | 142.34 | 90.15 | 61.25 | - | - |
EV/FCF Ratio | - | - | 274.21 | 268.94 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.19 | 1.13 | 1.02 | 0.12 | 0.13 | 1.18 |
Debt / EBITDA Ratio | 7.47 | 11.61 | 5.89 | 0.31 | - | - |
Debt / FCF Ratio | - | - | 19.60 | 1.54 | - | - |
Net Debt / Equity Ratio | 0.67 | 0.78 | -0.23 | -0.70 | -1.32 | -9.03 |
Net Debt / EBITDA Ratio | 4.70 | 10.02 | -1.34 | -1.89 | 1.52 | 0.25 |
Net Debt / FCF Ratio | -7.21 | -7.57 | -4.34 | -9.04 | 1.49 | 0.32 |
Asset Turnover | 0.70 | 0.76 | 0.85 | 1.48 | 0.88 | 0.06 |
Inventory Turnover | 12.58 | 13.90 | 10.84 | 14.01 | 10.92 | 1.25 |
Quick Ratio | 1.74 | 1.21 | 2.63 | 1.20 | 1.90 | 1.13 |
Current Ratio | 2.01 | 1.43 | 2.78 | 1.43 | 2.03 | 1.25 |
Return on Equity (ROE) | 7.36% | -1.85% | 14.79% | 5.36% | -253.34% | -198.36% |
Return on Assets (ROA) | 2.71% | 1.15% | 5.74% | 9.69% | -25.37% | -37.95% |
Return on Invested Capital (ROIC) | 6.78% | 3.81% | 32.69% | 537.03% | - | - |
Return on Capital Employed (ROCE) | 4.90% | 2.10% | 7.60% | 21.10% | -43.60% | -113.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 16, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.82% | -0.28% | 0.66% | 0.19% | -4.53% | -3.64% |
FCF Yield | -1.11% | -1.70% | 0.36% | 0.36% | -3.09% | -2.75% |
Buyback Yield / Dilution | -2.75% | 2.12% | -6.64% | -4.21% | -10.08% | -9.69% |